-
Ridogrel
- indication:Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.
- pharmacologypharmacology:
- mechanism: Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. Thromboxane synthetase produces thromboxane in platelets. Thromboxane is a vasoconstrictor and facilitates the clumping of platelets. Therefore by inhibiting the production and promotion of thromboxane, thrombolysis is enhanced.
- toxicity:
- absorprion: Rapidly absorbed after oral administration (30-60 min)
- halflife:
- roouteelimination:
- volumedistribution:
- clearance: